HOME
MEDICATIONS
PROGRAM SUPPLEMENTS
ABOUT US CONTACT
HOME
MEDICATIONS
PROGRAM SUPPLEMENTS
ABOUT US CONTACT
If you want to taper off the Wellbutrin and you are not sure where to start, you
can click here and
read the bestselling book, How to Get Off Psychoactive Drugs Safely or send Jim
Harper an email at
Jim@theroadback.org and he will guide you
through the process of Wellbutrin withdrawal.
If You Are Already Having Wellbutrin Withdrawal
click here
If you are experiencing brain zaps, electrical jolts in the head,
click here
Wellbutrin (bupropion) is a medication commonly prescribed for depression and to
aid smoking cessation. Like all medications, Wellbutrin can cause withdrawal
symptoms when it is stopped abruptly. In this response, we will discuss
Wellbutrin withdrawal in greater detail, including symptoms, causes, and
management strategies.
Wellbutrin withdrawal can occur when a person abruptly stops taking the
medication after a prolonged period of use. Withdrawal symptoms can begin as
early as a few hours after the last dose of Wellbutrin and can last for several
weeks. Some factors that can increase the likelihood and severity of Wellbutrin
withdrawal include a history of seizures or eating disorders, taking high doses
of the medication, and taking the medication for an extended period.
Symptoms of Wellbutrin withdrawal can vary in severity and duration. Common
symptoms include nausea and vomiting, dizziness or lightheadedness, headache,
insomnia, irritability or agitation, anxiety or panic attacks, fatigue or
lethargy, and flu-like symptoms, including muscle aches and chills. Some
individuals may also experience changes in mood, such as depression or
irritability, and in rare cases, suicidal thoughts or behavior.
The onset and duration of withdrawal symptoms can depend on a variety of
factors, including the dose and duration of Wellbutrin use, individual
differences in metabolism, and other medical conditions. For most people,
withdrawal symptoms begin within a few days of stopping Wellbutrin and can last
for up to several weeks. In some cases, symptoms may persist for several months.
To manage Wellbutrin withdrawal symptoms, healthcare providers will recommend a
gradual tapering schedule to slowly reduce the dosage of the medication. This
can help to minimize withdrawal effects and make the transition off the
medication smoother. Depending on the individual, tapering schedules can take
several weeks or even months. Other management strategies for Wellbutrin
withdrawal may include over-the-counter medications to relieve specific
symptoms, such as anti-nausea medication or pain relievers. Additionally,
lifestyle modifications such as regular exercise, a balanced diet, and stress
reduction techniques like mindfulness or meditation can help to alleviate
withdrawal symptoms and improve overall well-being.
It's important to note that while Wellbutrin withdrawal can be uncomfortable, it
is generally not life-threatening. However, in rare cases, seizures may occur,
especially in individuals with a history of seizures or eating disorders. If you
experience seizures or any other concerning symptoms during Wellbutrin
withdrawal, it's important to seek medical attention immediately.
In conclusion, Wellbutrin withdrawal can occur when a person abruptly stops
taking the medication after a prolonged period of use. Symptoms of Wellbutrin
withdrawal can include nausea and vomiting, dizziness or lightheadedness,
headache, insomnia, irritability or agitation, anxiety or panic attacks, fatigue
or lethargy, and flu-like symptoms. To manage Wellbutrin withdrawal symptoms,
healthcare providers may recommend a gradual tapering schedule to slowly reduce
the dosage of the medication. Other management strategies may include
over-the-counter medications, lifestyle modifications, and seeking medical
attention if symptoms worsen. If you are experiencing Wellbutrin withdrawal
symptoms, it's important to speak with your healthcare provider to discuss
management options and ensure your safety and well-being.
1. Hill S et al., “A Case Report of Seizure Induced by Bupropion Nasal Insufflation” Primary Care Companion to the Journal of Clinical Psychiatry [ 2007 ] PMID 17599174 [cited 2023 May 22]
2. Sub Laban T, Saadabadi A. Monoamine Oxidase Inhibitors (MAOI) [Updated 2021 Apr 16]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539848/ [cited 2023 May 22]
3. Victoria, “Difference Between Zyban and Wellbutrin” DifferenceBetween.net. 2011 Jan 27 [cited 2023 May 22]
4. FDA drug label “Wellbutrin (bupropion hydrochloride Tablets.” [N.D] Ref. No 2978172 [cited 2023 May 22]
5. Wooltorton E, “Health and Drug Alerts: Bupropion (Zyban, Wellbutrin SR) : reports of deaths, seizures, serum sickness.” CMAJ 2002 Jan 8, PMID 11800252 [cited 2023 May 22]
6. Wilson E, Lader M. A review of the management of antidepressant discontinuation symptoms. Ther Adv Psychopharmacol. 2015;5(6):357-368. doi:10.1177/2045125315612334 [cited 2023 May 22]
7. Xue C, Zhang X, Cai W. Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model. Pharmaceutics. 2017 Dec 21;10(1):1. doi: 10.3390/pharmaceutics10010001. PMID: 29267251; PMCID: PMC5874814. [cited 2023 May 22]
8. Berigan TR, Harazin JS. Bupropion-Associated Withdrawal Symptoms: A Case Report. Prim Care Companion J Clin Psychiatry. 1999;1(2):50-51. doi:10.4088/pcc.v01n0205 [cited 2023 May 22]
9. Berigan TR. Bupropion-Associated Withdrawal Symptoms Revisited: A Case Report. Prim Care Companion J Clin Psychiatry. 2002;4(2):78. doi:10.4088/pcc.v04n0208a [cited 2023 May 22]
10. Hill S, Sikand H, Lee J. A case report of seizure induced by bupropion nasal insufflation. Prim Care Companion J Clin Psychiatry. 2007;9(1):67-69. doi:10.4088/pcc.v09n0114a [cited 2023 May 22]
11. Cooper BR, Hester TJ, Maxwell RA. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther. 1980 Oct;215(1):127-34. PMID: 6778989. [cited 2023 May 22]
12. Stassinos GL, Klein-Schwartz W. Bupropion “Abuse” Reported to US Poison Centers. J Addict Med. 2016 Sep-Oct;10(5):357-62. doi: 10.1097/ADM.0000000000000249. PMID: 27504927.[cited 2023 May 22]
13. Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol. 2008 May;22(3):330-2. doi: 10.1177/0269881107081550. Erratum in: J Psychopharmacol. 2009 Nov;23(8):1006. PMID: 18515448. [cited 2023 May 22]
14. Lejoyeux M, Adès J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatry. 1997;58 Suppl 7:11-5; discussion 16. PMID: 9219488. [cited 2023 May 22]
15. Fava M, Rush AJ, Thase ME, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005;7(3):106-113. doi:10.4088/pcc.v07n0305 [cited 2023 May 22]
16. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6(4):159-166. doi:10.4088/pcc.v06n0403 [cited 2023 May 22]
17. Wilson E, Lader M. A review of the management of antidepressant discontinuation symptoms. Ther Adv Psychopharmacol. 2015;5(6):357-368. doi:10.1177/2045125315612334 [cited 2023 May 22]
18. Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom. 2018;87(4):195-203. doi: 10.1159/000491524. Epub 2018 Jul 17. PMID: 30016772. [cited 2023 May 22]
19. Huecker MR, Smiley A, Saadabadi A. Bupropion. [Updated 2023 Apr 9]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470212/ [cited 2023 July 14]
20. Strike M, Hatcher S. Bupropion injection resulting in tissue necrosis and psychosis: previously undocumented complications of intravenous bupropion use disorder. J Addict Med. 2015 May-Jun;9(3):246-50. doi: 10.1097/ADM.0000000000000114. PMID: 25822212. [cited 2023 May 22]
21. Munoli RN, Kongasseri S, Praharaj SK, Sharma PS. Bupropion precipitating acute psychosis: a case report. Am J Ther. 2014 Mar-Apr;21(2):e45-7. doi: 10.1097/MJT.0b013e31823581c8. PMID: 23698185. [cited 2023 May 22]
22. NIDA. Impacts of Drugs on Neurotransmission. National Institute on Drug Abuse website. March 9, 2017 [cited 2023 May 22]
23. Barry JD, Wills BK. Neurotoxic emergencies. Psychiatr Clin North Am. 2013 Jun;36(2):219-44. doi: 10.1016/j.psc.2013.02.003. Epub 2013 Apr 11. PMID: 23688689. [cited 2023 May 22]
24. Orisakwe OE. The role of lead and cadmium in psychiatry. N Am J Med Sci. 2014;6(8):370-376. doi:10.4103/1947-2714.139283 [cited 2023 May 22]
25. Rare Diseases Govt. Fact Sheet, “Heavy Metal Poisoning.” April 27, 2017[cited 2023 May 22]
26. Lissemore, J.I., Sookman, D., Gravel, P. et al. Brain serotonin synthesis capacity in obsessive-compulsive disorder: effects of cognitive behavioral therapy and sertraline. Transl Psychiatry 8, 82 (2018). [cited 2023 May 22]
27. Penckofer S, Kouba J, Byrn M, Estwing Ferrans C. Vitamin D and depression: where is all the sunshine?. Issues Ment Health Nurs. 2010;31(6):385-393. doi:10.3109/01612840903437657.[cited 2023 May 22]
28. Weir, K, “The Exercise Effect.” American Psychological Association Vol 42, No. 11 [cited 2023 May 22]
29. Understanding nutrition, depression and mental illnesses Indian J Psychiatry. 2008 Apr-Jun; 50(2): 77–82. T. S. Sathyanarayana Rao, M. R. Asha, B. N. Ramesh, and K. S. Jagannatha Rao. [cited 2023 May 22]
30. Hage MP, Azar ST. The Link between Thyroid Function and Depression. J Thyroid Res. 2012;2012:590648. doi:10.1155/2012/590648. [cited 2023 May 22]
31. Schifano F, Chiappini S, Corkery JM, Guirguis A. Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. Brain Sci. 2018 Apr 22;8(4):73. doi: 10.3390/brainsci8040073. PMID: 29690558; PMCID: PMC5924409. [cited 2023 May 22]
32. DOJ “GlaxoSmithKlein to Plead Guilty and to pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data, Largest Health Fraud Settlement in US History” [published online] [cited 2023 May 22]
33. Stall N, Godwin J, Juurlink D. Bupropion abuse and overdose. CMAJ. 2014;186(13):1015. doi:10.1503/cmaj.131534 [cited 2023 May 22]
34. van Praag HM. Serotonin precursors in the treatment of depression. Adv Biochem Psychopharmacol. 1982;34:259-86. PMID: 6753514. [cited 2023 May 22]
35. Zagorski N, American Psychiatric Assn News FDA Approves Rapid-Acting Oral Antidepressant [published 24 Oct 2022 online] [cited 2023 May 22]
36. FDA label Auvellty (extromethorphan hydrobromide and bupropion HCL) extended-release tablets for oral use [cited 2023 May 22]
37. CDC Data Brief #347 Prescription Drug Use Among Adults Aged 40-79 in the US and Canada [published August 2019] [cited 2023 Aug 8]
38. Gadde KM, Parker CB, Maner LG, Wagner HR 2nd, Logue EJ, Drezner MK, Krishnan KR. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001 Sep;9(9):544-51. doi: 10.1038/oby.2001.71. PMID: 11557835. [cited 2023 Aug 8]
39. Bystritsky RJ. Cellulitis. Infect Dis Clin North Am. 2021 Mar;35(1):49-60. doi: 10.1016/j.idc.2020.10.002. PMID: 33494874. [cited 2023 Aug 8]
40. Khalid N, Azimpouran M. Necrosis. [Updated 2023 Mar 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557627/ [cited 2023 Aug 8]